Acute coronary syndrome (ACS) within 3 months.
Under beta-blocker treatment for the last 2 weeks.
Under other medicine treatment which may affect heart rate, like Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine for the last 2 weeks; Under Digoxin treatment [more than (>) 0.125 milligram (mg)].
Uncontrolled Diabetes [hemoglobin A1c, (HbA1c) >7.5%].
Severe or uncontrolled hypertension [resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg at screening period].
Severe hypotension [resting SBP less than (<) 90mmHg, or resting DBP<50mmHg].
Resting heart rate <60 beat per minute (bpm).
Any contradiction to Bisoprolol according to label, including:
Acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy.
Cardiogenic shock.
Atrioventricular block of second or third degree (without a pacemaker).
Sick sinus syndrome.
Sinoatrial block.
Slowed heart rate, causing symptoms (symptomatic bradycardia),
Decreased blood pressure, causing symptoms (symptomatic hypotension),
Severe bronchial asthma or severe chronic obstructive pulmonary disease.
Sever forms of peripheral arterial occlusive disease and Raynaud's syndrome.
Untreated phaeochromocytoma.
Metabolic acidosis.
Hypersensitivity to bisoprolol or to any of the excipients.
Severe Arrhythmia including atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia.
Significant valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease.
Acute pulmonary edema.
Severe hepatic dysfunction, defined as:
Serum Alanine Aminotransferase (ALT) > triple the upper limit of the normal range; and/or
Serum Aspartate Aminotransferase (AST) > triple the upper limit of the normal value range and/or
Severe renal dysfunction, defined as:
Serum creatinine > twice the upper limit of the normal range
Chronic Kidney Disease (glomerular filtration rate <45 Milliliter per minute).
Hyperthyroidism or hypothyroidism.
Severe infectious disease, example (eg) Human Immunodeficiency Virus positive or active tuberculosis.
Severe autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.
Severe respiratory, digestive, hematological disease (including Anemia of Hb < 100 gram per litre) or tumor.
Known to be hypersensitivity to Bisoprolol, or any of the excipient.
Substance or alcohol abuse.
Received heart transplantation or pacemaker implantation; revascularization treatment within 3 months; or plan to receive above treatment in 6 months.
Currently undertaking other treatment that may affect the safety and/or efficacy evaluation, e.g. beta receptors agonists, et cetera.
No legal ability or legal ability is limited.
Subjects unlikely to cooperate in the study or with inability or unwillingness to give informed consent.
Child-bearing period women without effective contraceptive measures, pregnancy and lactation.
Participation in another clinical trial within the past 90 days.
Other significant condition that in the Investigator's opinion would exclude the subject from the trial.

NCT03026088_exc_T1
Condition
Acute coronary syndrome
NCT03026088_exc_T2
Condition
ACS
NCT03026088_exc_T3
Temporal
within 3 months
NCT03026088_exc_T4
Drug
beta-blocker
NCT03026088_exc_T5
Temporal
for the last 2 weeks
NCT03026088_exc_T6
Drug
Non-dihydropyridine calcium channel blockers
NCT03026088_exc_T7
Drug
NDHP-CCBs
NCT03026088_exc_T8
Drug
ivabradine
NCT03026088_exc_T9
Temporal
for the last 2 weeks
NCT03026088_exc_T10
Drug
Digoxin
NCT03026088_exc_T11
Multiplier
re than ( 125 milligram (
NCT03026088_exc_T12
Value
125 m )]
NCT03026088_exc_T13
Scope
Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine
NCT03026088_exc_T15
Condition
Diabetes
NCT03026088_exc_T16
Qualifier
Uncontrolled
NCT03026088_exc_T17
Measurement
hemoglobin A1c
NCT03026088_exc_T18
Measurement
HbA1c
NCT03026088_exc_T19
Value
>7.5%
NCT03026088_exc_T20
Condition
hypertension
NCT03026088_exc_T21
Qualifier
uncontrolled
NCT03026088_exc_T22
Qualifier
Severe
NCT03026088_exc_T23
Scope
Severe or uncontrolled
NCT03026088_exc_T24
Measurement
Systolic Blood Pressure
NCT03026088_exc_T25
Measurement
SBP
NCT03026088_exc_T26
Value
>180 millimeters of mercury
NCT03026088_exc_T27
Value
 mi ), o
NCT03026088_exc_T28
Measurement
Diastolic Blood Pressure
NCT03026088_exc_T29
Measurement
DBP
NCT03026088_exc_T30
Value
>110mmHg
NCT03026088_exc_T31
Temporal
at screening period
NCT03026088_exc_T32
Reference_point
screening
NCT03026088_exc_T33
Qualifier
resting
NCT03026088_exc_T34
Qualifier
resting
NCT03026088_exc_T35
Scope
resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg at screening period
NCT03026088_exc_T36
Scope
resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg
NCT03026088_exc_T37
Condition
hypotension
NCT03026088_exc_T38
Qualifier
Severe
NCT03026088_exc_T39
Measurement
SBP
NCT03026088_exc_T40
Value
than (<) g, or
NCT03026088_exc_T41
Qualifier
resting
NCT03026088_exc_T42
Qualifier
resting
NCT03026088_exc_T43
Measurement
DBP
NCT03026088_exc_T44
Value
<50mmHg
NCT03026088_exc_T45
Scope
resting SBP less than (<) 90mmHg, or resting DBP<50mmHg
NCT03026088_exc_T46
Measurement
heart rate
NCT03026088_exc_T47
Qualifier
Resting
NCT03026088_exc_T48
Value
<60 beat per minute
NCT03026088_exc_T49
Value
at Any
NCT03026088_exc_T50
Drug
Bisoprolol
NCT03026088_exc_T51
Condition
contradiction
NCT03026088_exc_T52
Condition
Acute heart failure
NCT03026088_exc_T53
Condition
heart failure decompensation
NCT03026088_exc_T54
Procedure
intravenous inotropic therapy
NCT03026088_exc_T55
Condition
Cardiogenic shock
NCT03026088_exc_T56
Condition
icular block of second or third thout
NCT03026088_exc_T57
Condition
icular block of second or ee (without
NCT03026088_exc_T58
Device
pacemaker
NCT03026088_exc_T59
Negation
without
NCT03026088_exc_T60
Condition
Sick sinus syndrome
NCT03026088_exc_T61
Condition
Sinoatrial block
NCT03026088_exc_T62
Condition
heart rate
NCT03026088_exc_T63
Qualifier
Slowed
NCT03026088_exc_T64
Condition
bradycardia
NCT03026088_exc_T65
Qualifier
symptomatic
NCT03026088_exc_T66
Condition
symptoms
NCT03026088_exc_T67
Condition
blood pressure
NCT03026088_exc_T68
Qualifier
Decreased
NCT03026088_exc_T69
Condition
symptoms
NCT03026088_exc_T70
Condition
hypotension
NCT03026088_exc_T71
Qualifier
symptomatic
NCT03026088_exc_T72
Condition
bronchial asthma
NCT03026088_exc_T73
Qualifier
Severe
NCT03026088_exc_T74
Condition
chronic obstructive pulmonary disease
NCT03026088_exc_T75
Qualifier
severe
NCT03026088_exc_T76
Condition
peripheral arterial occlusive disease
NCT03026088_exc_T77
Condition
Raynaud's syndrome
NCT03026088_exc_T78
Qualifier
Sever
NCT03026088_exc_T79
Scope
peripheral arterial occlusive disease and Raynaud's syndrome
NCT03026088_exc_T81
Condition
phaeochromocytoma
NCT03026088_exc_T82
Qualifier
Untreated
NCT03026088_exc_T83
Condition
Metabolic acidosis
NCT03026088_exc_T84
Condition
Hypersensitivity
NCT03026088_exc_T85
Drug
bisoprolol
NCT03026088_exc_T86
Drug
excipients
NCT03026088_exc_T87
Qualifier
any
NCT03026088_exc_T88
Scope
bisoprolol or to any of the excipients
NCT03026088_exc_T89
Condition
Arrhythmia
NCT03026088_exc_T90
Qualifier
Severe
NCT03026088_exc_T91
Condition
atrial fibrillation
NCT03026088_exc_T92
Condition
atrial flutter
NCT03026088_exc_T93
Condition
ventricular fibrillation
NCT03026088_exc_T94
Condition
ventricular flutter
NCT03026088_exc_T95
Condition
ventricular tachycardia
NCT03026088_exc_T96
Scope
atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia
NCT03026088_exc_T97
Condition
valvular heart disease
NCT03026088_exc_T98
Qualifier
Significant
NCT03026088_exc_T99
Condition
congenital heart disease
NCT03026088_exc_T100
Condition
pulmonary heart disease
NCT03026088_exc_T101
Condition
perinatal heart disease
NCT03026088_exc_T102
Scope
valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease
NCT03026088_exc_T103
Condition
Acute pulmonary edema
NCT03026088_exc_T104
Condition
hepatic dysfunction
NCT03026088_exc_T105
Qualifier
Severe
NCT03026088_exc_T106
Measurement
Serum Alanine Aminotransferase
NCT03026088_exc_T107
Measurement
ALT
NCT03026088_exc_T108
Value
> triple the upper limit of the normal range
NCT03026088_exc_T110
Measurement
Serum Aspartate Aminotransferase
NCT03026088_exc_T111
Measurement
AST
NCT03026088_exc_T112
Value
> triple the upper limit of the normal value range
NCT03026088_exc_T114
Condition
renal dysfunction
NCT03026088_exc_T115
Qualifier
Severe
NCT03026088_exc_T116
Measurement
Serum creatinine
NCT03026088_exc_T117
Value
> twice the upper limit of the normal range
NCT03026088_exc_T118
Condition
Chronic Kidney Disease
NCT03026088_exc_T119
Measurement
glomerular filtration rate
NCT03026088_exc_T120
Value
<45 Milliliter per minute
NCT03026088_exc_T121
Condition
Hyperthyroidism
NCT03026088_exc_T122
Condition
hypothyroidism
NCT03026088_exc_T123
Condition
infectious disease
NCT03026088_exc_T124
Qualifier
Severe
NCT03026088_exc_T125
Condition
Human Immunodeficiency Virus positive
NCT03026088_exc_T127
Condition
tuberculosis
NCT03026088_exc_T128
Qualifier
active
NCT03026088_exc_T126
Scope
Human Immunodeficiency Virus positive or active tuberculosis
NCT03026088_exc_T129
Condition
autoimmune disease
NCT03026088_exc_T130
Qualifier
Severe
NCT03026088_exc_T131
Condition
lupus erythematosus
NCT03026088_exc_T132
Condition
multiple sclerosis
NCT03026088_exc_T133
Scope
lupus erythematosus, multiple sclerosis
NCT03026088_exc_T134
Condition
gical disea < 100 g
NCT03026088_exc_T135
Condition
 (includ < 100 g
NCT03026088_exc_T136
Condition
hematological disease
NCT03026088_exc_T137
Qualifier
Severe
NCT03026088_exc_T138
Scope
respiratory, digestive, hematological disease
NCT03026088_exc_T139
Condition
Anemia
NCT03026088_exc_T140
Measurement
Hb
NCT03026088_exc_T141
Value
< 100 gram per litre
NCT03026088_exc_T142
Condition
tumor
NCT03026088_exc_T143
Condition
hypersensitivity
NCT03026088_exc_T144
Drug
Bisoprolol
NCT03026088_exc_T145
Drug
excipient
NCT03026088_exc_T146
Qualifier
any
NCT03026088_exc_T147
Scope
Bisoprolol, or any of the excipient
NCT03026088_exc_T148
Condition
alcohol abuse
NCT03026088_exc_T149
Condition
ed heart ion o
NCT03026088_exc_T150
Procedure
heart transplantation
NCT03026088_exc_T151
Procedure
pacemaker implantation
NCT03026088_exc_T152
Procedure
revascularization
NCT03026088_exc_T153
Temporal
within 3 months
NCT03026088_exc_T154
Mood
plan to
NCT03026088_exc_T155
Temporal
in 6 months
NCT03026088_exc_T156
Scope
heart transplantation or pacemaker implantation; revascularization
NCT03026088_exc_T157
Procedure
heart transplantation
NCT03026088_exc_T158
Procedure
pacemaker implantation
NCT03026088_exc_T159
Procedure
revascularization
NCT03026088_exc_T160
Scope
heart transplantation or pacemaker implantation; revascularization
NCT03026088_exc_T162
Drug
beta receptors agonists